<Suppliers Price>

Enclomiphene hydrochloride

Names

[ CAS No. ]:
14158-65-7

[ Name ]:
Enclomiphene hydrochloride

[Synonym ]:
Enclomiphene hydrochloride
2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine,hydrochloride

Biological Activity

[Description]:

Enclomiphene ((E)-Clomiphene) hydrochloride is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene hydrochloride can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes[1].

[Related Catalog]:

Signaling Pathways >> Others >> Estrogen Receptor/ERR
Research Areas >> Endocrinology
Research Areas >> Metabolic Disease

[In Vitro]

Enclomiphene hydrochloride (0-100 μM, 6 h) dose-dependently inhibits basal and gonadotrophin-stimulated small and large ovine luteal cell progesterone secretion[2]. Enclomiphene hydrochloride (0-100 μg/mL, 24 h) dose-dependently inhibits fertilization rates, blastocyst formation rates, and degeneration rates in mouse oocytes[3]. Enclomiphene hydrochloride (1 nM-10 μM, 6 h) dose-dependently decreases E2-induced inhibition of follicle stimulating hormone (FSH) secretion in primary sheep pituitary cells[4].

[In Vivo]

Enclomiphene hydrochloride (subcutaneous injection, 0.25 and 0.5 mg/animal, daily) inhibits spermatogenesis and decreases serum luteinizing hormone (LH) and testosterone levels in intact or castrated rats[5]. Enclomiphene hydrochloride (oral adminstration, 0.03-3 mg/kg, daily for 90 days) reductes body weight to sham levels, and reduced serum cholesterol[6]. Animal Model: 21 days-old Charles River male rats[5] Dosage: 0.25 and 0.5 mg/animal, daily for 24 days. Administration: Subcutaneous injection Result: Decreased LH and testosterone levels in the serum. Animal Model: OVX (ovariectomy) rat model[6] Dosage: 0.03, 1, and 3 mg/kg, daily for 90 days. Administration: Oral adminstration Result: Reducted body weight to sham levels, and reduced serum cholesterol. Showed dose-dependent effects on the proximal tibia with BMD and BMC approaching posttreatment Sham levels.

[References]

[1]. Rodriguez KM, et al. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016 Aug;17(11):1561-7.

[2]. M S Opsahl, et al. Effects of enclomiphene and zuclomiphene on basal and gonadotrophin-stimulated progesterone secretion by isolated subpopulations of small and large ovine luteal cells. Hum Reprod. 1996 Jun;11(6):1250-5.

[3]. G E Schmidt, et al. The effects of enclomiphene and zuclomiphene citrates on mouse embryos fertilized in vitro and in vivo. Am J Obstet Gynecol. 1986 Apr;154(4):727-36.

[4]. E S Huang, et al. Estrogenic and antiestrogenic effects of enclomiphene and zuclomiphene on gonadotropin secretion by ovine pituitary cells in culture. Endocrinology. 1983 Feb;112(2):442-8.

[5]. R Weissenberg, et al. The effect of clomiphene citrate and its Zu or En isomers on the reproductive system of the immature male rat. Andrologia. 1992 May-Jun;24(3):161-5.

[6]. R T Turner, et al. Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology. 1998 Sep;139(9):3712-20.

Chemical & Physical Properties

[ Molecular Formula ]:
C26H29Cl2NO

[ Molecular Weight ]:
442.42100

[ Exact Mass ]:
441.16300

[ PSA ]:
12.47000

[ LogP ]:
7.36460

MSDS

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Articles

Bone Mineral Density and Response to Treatment in Men Younger Than 50 Years with Testosterone Deficiency and Sexual Dysfunction or Infertility

J. Urol. 191(4) , 1072-6, (2014)

Purpose Testosterone deficiency is a known risk factor for osteopenia and osteoporosis in older men. Less is known about the impact of testosterone deficiency on bone mineral density in younger men.

Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis

Fertil. Steril. 100(5) , 1373-80, (2013)

Objective To evaluate the effect of luteal phase P support after ovulation induction IUI.

Re: Optimization of Spermatogenesis-Regulating Hormones in Patients with Non-Obstructive Azoospermia and its Impact on Sperm Retrieval: A Multicentre Study

J. Urol. 190(6) , 2209, (2013)


More Articles